Bullish Case: Known: TARS at $66.17 is flat over ~90d; call volume > put volume and sentiment is cautiously optimistic. From the term-structure graph, IV is mildly contango (later IV slightly higher), consistent with non-binary evolution; near-spot IV is mid-range while far-OTM puts are the extreme risk. From the return-surface, highest likelihood clusters around small positive returns. Inferred: mean-reversion upward remains viable, but prior “drift” calls ran less than expected.

Bearish Case: Known: far-OTM put IV on the TARS vol-surface is extremely elevated (market pricing a hidden downside tail), even though SPY IV looks comparatively calmer. Inferred: if XDEMVY monetization (Rx velocity/retreatment cadence) disappoints or payer leverage worsens, that tail can express as a volatility/price coupling selloff. Calibration: earlier >20% drawdown was not realized, so bearish odds are lower than before, but “company-specific shock” risk persists.

Potential Outcomes:

1. 35%: -3–+5% chop; falsify if Rx velocity/guidance trims.
2. 30%: +5–12% drift; contango + return-surface positive density; falsify if uptake decelerates.
3. 20%: -8–15%; far-OTM put-IV stays bid; falsify if payer economics worsen.
4. 10%: +18–30% pop; if pipeline/XDEMVY update surprises; falsify if delays/miss.
5. 5%: ≤-25% crash; regulatory/label shock; falsify if no adverse news.

June 24, 2026